Australian Government bans replicas of Ozempic and Mounjaro
Welcoming bans
Diabetes Victoria welcomes the Federal Government’s decision to ban replica versions of Ozempic and other type 2 diabetes medications.
Ordered to stop production
Pharmacies compounding their own versions of these drugs have been ordered to stop production from October 1, 2024.
Under new regulations, glucagon-like peptide-1 receptor agonists (GLP-1RAs), many claiming to be replicas of Ozempic and Mounjaro, will be removed from pharmacy compounding exemption.
Currently, this exemption allows compounding pharmacists to reproduce these drugs in times of shortage, however they are not subject to the same safety checks.
While we recognise the concerns of the diabetes community amid the global shortage of Ozempic (semaglutide), the compounded products have not been evaluated by the TGA for safety, quality, and efficacy.
Diabetes Victoria will continue to advocate for priority access to Ozempic for people living with diabetes.
More information about the safety of these products can be found on the TGA website.
